Cover Image
市場調查報告書

老年癡呆症:開發平台分析

Alzheimer's Disease - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232776
出版日期 內容資訊 英文 1216 Pages
訂單完成後即時交付
價格
Back to Top
老年癡呆症:開發平台分析 Alzheimer's Disease - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 1216 Pages
簡介

老年癡呆症,是進行性且慢慢症狀惡化的疾病,神經受侵襲而發生記憶和行動障礙。 神經進行信號傳送的神經傳達物質乙醯膽鹼的合成,受破壞的話信號傳達斷絕最終記憶和行動功能產生障礙。年齡、遺傳、循環系統疾病、糖尿病、環境的要素等,各式各樣的因素讓老年癡呆症發病的風險高漲。也有引起各種併發症的情況,不進行治療的話也可能致命。

本報告提供老年癡呆症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新新聞和發表。

簡介

  • 老年癡呆症 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9616IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H2 2017, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 23, 49, 57, 2, 257, 94 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 111 and 47 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Alzheimer's Disease - Overview
  • Alzheimer's Disease - Therapeutics Development
  • Alzheimer's Disease - Therapeutics Assessment
  • Alzheimer's Disease - Companies Involved in Therapeutics Development
  • Alzheimer's Disease - Drug Profiles
  • Alzheimer's Disease - Dormant Projects
  • Alzheimer's Disease - Discontinued Products
  • Alzheimer's Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Alzheimer's Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..15), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..16), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..14), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..15), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..16), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..17), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..18), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..19), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..20), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..21), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..22), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..23), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..24), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..25), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..6), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..7), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Alzheimer's Disease - Pipeline by AB Science SA, H2 2017
  • Alzheimer's Disease - Pipeline by AbbVie Inc, H2 2017
  • Alzheimer's Disease - Pipeline by AC Immune SA, H2 2017
  • Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Accera Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Aequus Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Affibody AB, H2 2017
  • Alzheimer's Disease - Pipeline by AFFiRiS AG, H2 2017
  • Alzheimer's Disease - Pipeline by Alector LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Allergan Plc, H2 2017
  • Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Allinky Biopharma, H2 2017
  • Alzheimer's Disease - Pipeline by ALSP Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Alzinova AB, H2 2017
  • Alzheimer's Disease - Pipeline by AlzProtect SAS, H2 2017
  • Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Amgen Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Annexon Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Aphios Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Apodemus AB, H2 2017
  • Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H2 2017
  • Alzheimer's Disease - Pipeline by Aptevo Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Araclon Biotech SL, H2 2017
  • Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by ArmaGen Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Asceneuron SA, H2 2017
  • Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H2 2017
  • Alzheimer's Disease - Pipeline by AstraZeneca Plc, H2 2017
  • Alzheimer's Disease - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H2 2017
  • Alzheimer's Disease - Pipeline by Axovant Sciences Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Axxam SpA, H2 2017
  • Alzheimer's Disease - Pipeline by Beactica AB, H2 2017
  • Alzheimer's Disease - Pipeline by Berg LLC, H2 2017
  • Alzheimer's Disease - Pipeline by BioArctic AB, H2 2017
  • Alzheimer's Disease - Pipeline by Bioasis Technologies Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Biogen Inc, H2 2017
  • Alzheimer's Disease - Pipeline by BioHealthonomics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H2 2017
  • Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Alzheimer's Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Alzheimer's Disease - Pipeline by Bsim2, H2 2017
  • Alzheimer's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Cardax Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Carna Biosciences Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Celon Pharma SA, H2 2017
  • Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Clera Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Cognition Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Cognosci Inc, H2 2017
  • Alzheimer's Disease - Pipeline by CohBar Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by ConSynance Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Corium International Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Coronis NeuroSciences Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Cortice Biosciences Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Crossbeta Biosciences BV, H2 2017
  • Alzheimer's Disease - Pipeline by Daval International Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Denali Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Domain Therapeutics SA, H2 2017
  • Alzheimer's Disease - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Eisai Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Eli Lilly and Company, H2 2017
  • Alzheimer's Disease - Pipeline by Endece LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Ensemble Therapeutics Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Ensol Biosciences Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Epigen Biosciences Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Evotec AG, H2 2017
  • Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Genentech Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Genzyme Corp, H2 2017
  • Alzheimer's Disease - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Alzheimer's Disease - Pipeline by GliaCure Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Glialogix Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Golden Biotechnology Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Grifols SA, H2 2017
  • Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2017
  • Alzheimer's Disease - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by HitGen LTD, H2 2017
  • Alzheimer's Disease - Pipeline by ICB International Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Ichor Medical Systems Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Icure Pharmaceutical Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Immungenetics AG, H2 2017
  • Alzheimer's Disease - Pipeline by Immunwork Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Impel NeuroPharma Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by IntelGenx Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Intellect Neurosciences Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Io Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Johnson & Johnson, H2 2017
  • Alzheimer's Disease - Pipeline by K-Stemcell Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Kadmon Corp LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Karuna Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by KineMed Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Lead Discovery Center GmbH, H2 2017
  • Alzheimer's Disease - Pipeline by Les Laboratoires Servier SAS, H2 2017
  • Alzheimer's Disease - Pipeline by Lipopharma Therapeutics SL, H2 2017
  • Alzheimer's Disease - Pipeline by Living Cell Technologies Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Lupin Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by M3 Biotechnology Inc, H2 2017
  • Alzheimer's Disease - Pipeline by ManRos Therapeutics, H2 2017
  • Alzheimer's Disease - Pipeline by MedDay SA, H2 2017
  • Alzheimer's Disease - Pipeline by Medesis Pharma SA, H2 2017
  • Alzheimer's Disease - Pipeline by Medestea Research & Production SpA, H2 2017
  • Alzheimer's Disease - Pipeline by MedImmune LLC, H2 2017
  • Alzheimer's Disease - Pipeline by MEDRx Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by MEI Pharma Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Merck & Co Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Microlin Bio Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Mithridion Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Alzheimer's Disease - Pipeline by ModGene Pharma LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Montisera Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Nanomerics Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Nanotherapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by NeoNeuro SAS, H2 2017
  • Alzheimer's Disease - Pipeline by Neuralstem Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Neuro-Sys SAS, H2 2017
  • Alzheimer's Disease - Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by NeuroNascent Inc, H2 2017
  • Alzheimer's Disease - Pipeline by NeurOp Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Neuropore Therapies Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Neurotez Inc, H2 2017
  • Alzheimer's Disease - Pipeline by New World Laboratories Inc, H2 2017
  • Alzheimer's Disease - Pipeline by nLife Therapeutics SL, H2 2017
  • Alzheimer's Disease - Pipeline by NoNO Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Novartis AG, H2 2017
  • Alzheimer's Disease - Pipeline by Nymox Pharmaceutical Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Orphit SAS, H2 2017
  • Alzheimer's Disease - Pipeline by Oryzon Genomics SA, H2 2017
  • Alzheimer's Disease - Pipeline by Otsuka Holdings Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Ovensa Inc, H2 2017
  • Alzheimer's Disease - Pipeline by P2D Bioscience, H2 2017
  • Alzheimer's Disease - Pipeline by Pain Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Peptron Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Pfizer Inc, H2 2017
  • Alzheimer's Disease - Pipeline by PharmaKure Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Pharmaxis Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Pharnext SA, H2 2017
  • Alzheimer's Disease - Pipeline by Prevacus Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Probiodrug AG, H2 2017
  • Alzheimer's Disease - Pipeline by Progenra Inc, H2 2017
  • Alzheimer's Disease - Pipeline by ProMIS Neurosciences Inc, H2 2017
  • Alzheimer's Disease - Pipeline by ProQR Therapeutics NV, H2 2017
  • Alzheimer's Disease - Pipeline by Proteome Sciences Plc, H2 2017
  • Alzheimer's Disease - Pipeline by Proteostasis Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by QR Pharma Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Quimatryx SL, H2 2017
  • Alzheimer's Disease - Pipeline by Radius Health Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Regenera Pharma Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by reMYND NV, H2 2017
  • Alzheimer's Disease - Pipeline by Resverlogix Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Rodos BioTarget GmbH, H2 2017
  • Alzheimer's Disease - Pipeline by Sage Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Samjin Pharm Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Samumed LLC, H2 2017
  • Alzheimer's Disease - Pipeline by SanBio Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Sangamo Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Sanofi, H2 2017
  • Alzheimer's Disease - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by SeneXta Therapeutics SA, H2 2017
  • Alzheimer's Disease - Pipeline by Serometrix LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Shire Plc, H2 2017
  • Alzheimer's Disease - Pipeline by Signum Biosciences Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Simcere Pharmaceutical Group, H2 2017
  • Alzheimer's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Spherium Biomed SL, H2 2017
  • Alzheimer's Disease - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Summit Therapeutics Plc, H2 2017
  • Alzheimer's Disease - Pipeline by Suven Life Sciences Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by T3D Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by TauRx Therapeutics Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by TechnoPhage SA, H2 2017
  • Alzheimer's Disease - Pipeline by Teikoku Pharma USA Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Telocyte LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Tetra Discovery Partners LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Therapix Biosciences Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Toyama Chemical Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Treventis Corp, H2 2017
  • Alzheimer's Disease - Pipeline by UCB SA, H2 2017
  • Alzheimer's Disease - Pipeline by Varinel Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Virobay Inc, H2 2017
  • Alzheimer's Disease - Pipeline by VLP Therapeutics LLC, H2 2017
  • Alzheimer's Disease - Pipeline by Voyager Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by vTv Therapeutics Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Vybion Inc, H2 2017
  • Alzheimer's Disease - Pipeline by Wellstat Therapeutics Corp, H2 2017
  • Alzheimer's Disease - Pipeline by Xigen SA, H2 2017
  • Alzheimer's Disease - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017
  • Alzheimer's Disease - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..6), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..7), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..8), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..9), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..10), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..11), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..12), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..13), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..14), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..15), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..16), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..17), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..18), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..19), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..20), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..21), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..22), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..23), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..24), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..25), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..26), H2 2017
  • Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..27), H2 2017
  • Alzheimer's Disease - Discontinued Products, H2 2017
  • Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..1), H2 2017
  • Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..2), H2 2017
  • Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..3), H2 2017
  • Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..4), H2 2017
  • Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..5), H2 2017

List of Figures

  • Number of Products under Development for Alzheimer's Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top